Cefabactin vet.

25 x 10 pc

Tablet

Active substance

Cefalexin (Cefalexin monohydrate) : 250 mg

ATC code

QJ01DB01 Cefalexin

QJ01DB First-generation cephalosporins

QJ01D Other beta-lactam antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Dogs and cats.

Indications

For the treatment of:

- Respiratory tract infections, especially bronchopneumonia, caused by Staphylococcus aureus, Streptococcus spp., Escherichia coli and Klebsiella spp.

- Urinary tract infections caused by Escherichia coli, Proteus spp. and Staphylococcus spp.

- Skin infections in cats caused by Staphylococcus spp. and Streptococcus spp. and skin infections in dogs caused by Staphylococcus spp.

Dose to be administered and administration route

For oral use.

The recommended dose is 15-30 mg cefalexin per kg body weight twice a day, during at least 5 consecutive days. An extended course of treatment may be prescribed by the responsible veterinarian in cases of, for example, urinary tract infections or bacterial dermatitis.

To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

The following table is intended as a guide to dispensing the veterinary medicinal product at a dose rate of 15 mg cefalexine per kg body weight twice a day.

= ¼ Tablet = ½ Tablet = ¾ Tablet = 1 Tablet

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface with its scored side facing up.

Halves: press down with your thumbs on both sides of the tablet.

Quarters: press down with your thumb in the middle of the tablet.

Adverse reactions

Dogs:

Rare

(1 to 10 animals / 10,000 animals treated):

Hypersensitivity reaction^a

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Vomiting ^b, Diarrhoea ^b, Lethargy

^a The treatment should be discontinued.

^b In case of recurrence, the treatment should be discontinued and the advice of the attending veterinarian sought.

Cats:

Very common

(>1 animal / 10 animals treated):

Vomiting^a, Diarrhoea^a

Rare

(1 to 10 animals / 10,000 animals treated):

Hypersensitivity reaction^b

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Lethargy

^a Mild and transient. The symptoms were reversible in most cats without symptomatic treatment.

^b The treatment should be discontinued.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.